Latest news with #2024InducementPlan
Globe and Mail
02-05-2025
- Business
- Globe and Mail
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on May 1, 2025, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 3,688 shares of its common stock to five new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock units were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest in four equal annual installments, subject to each employee's continued employment with Praxis on each vesting date. About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit and follow us on Facebook, LinkedIn and Twitter/X.
Yahoo
02-04-2025
- Business
- Yahoo
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, England & BOSTON, April 02, 2025--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on April 1, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 32,400 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price equal to $8.49 per share, Bicycle Therapeutics' closing trading price on March 31, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the employees' continued service relationship with the company through the applicable vesting dates. The awards are subject to the terms and conditions of Bicycle Therapeutics' 2024 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant. About Bicycle Therapeutics Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Drug Conjugate (BDC™) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BDC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit View source version on Contacts Investors: Stephanie YaoSVP, Investor Relations and Corporate 857-523-8544 Matthew DeYoungArgot Partnersir@ 212-600-1902 Media: Jim O'ConnellWeber Shandwickmedia@ 312-988-2343 Sign in to access your portfolio
Associated Press
19-03-2025
- Business
- Associated Press
Etsy Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BROOKLYN, N.Y., March 19, 2025 /PRNewswire/ -- Etsy, Inc. (Nasdaq: ETSY), which operates two-sided online marketplaces that connect millions of passionate and creative buyers and sellers around the world, today announced that on March 17, 2025, Etsy granted an inducement performance stock unit award consisting of 45,064 shares of Etsy's common stock to Lanny Baker, who joined Etsy as its Chief Financial Officer effective January 1, 2025. The awards were granted under the Etsy, Inc. 2024 Inducement Plan (the '2024 Inducement Plan') as a material inducement to Mr. Baker's entering into employment with Etsy, in accordance with Nasdaq Listing Rule 5635(c)(4). The performance stock units are earned based on Etsy's achievement of certain performance targets set by Etsy's Compensation Committee, and vest over a three year performance period subject to continued employment with Etsy through each vesting date. The performance stock units are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of a performance stock unit agreement covering the grant. The 2024 Inducement Plan was adopted by Etsy's Board of Directors on December 12, 2024, and may only be used for grants to employees commencing employment with Etsy, or being rehired following a bona fide period of non-employment, and must provide a material inducement to entering into such employment, pursuant to Nasdaq Listing Rule 5635(c)(4). About Etsy Etsy, Inc. operates two-sided online marketplaces that connect millions of passionate and creative buyers and sellers around the world. These marketplaces share a mission to 'Keep Commerce Human,' and we're committed to using the power of business and technology to strengthen communities and empower people. Our primary marketplace, is the global destination for unique and creative goods. Buyers come to Etsy to be inspired and delighted by items that are crafted and curated by creative entrepreneurs. For sellers, we offer a range of tools and services that address key business needs. Etsy, Inc.'s 'House of Brands' portfolio also includes Reverb Holdings, Inc. our musical instrument marketplace, and Depop Limited, our fashion resale marketplace. Each Etsy, Inc. marketplace primarily operates independently, while benefiting from shared expertise in product development, marketing, technology, and customer support. Etsy was founded in 2005 and is headquartered in Brooklyn, New York. Etsy has used, and intends to continue using, its Investor Relations website and the Etsy News Blog ( to disclose material non-public information and to comply with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website and the Etsy News Blog in addition to following our press releases, SEC filings, and public conference calls and webcasts.
Yahoo
14-03-2025
- Business
- Yahoo
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 14, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 5, 2025, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 71,981 shares of common stock and 42,159 restricted stock units ("RSUs") to thirteen new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $18.08 per share, Acadia's closing trading price on March 5, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Acadia through the applicable vesting dates. The RSUs will vest over four years, with 50% of the underlying shares vesting on the second anniversary of the grant date, and the balance of the underlying shares vesting in two equal annual installments measured from the second anniversary of the grant date, subject to the new employees' continued service relationship with Acadia through the applicable vesting dates. The awards are subject to the terms and conditions of Acadia's 2024 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. View source version on Contacts Investor Contact: Acadia Pharmaceuticals Kildani(858) 261-2872ir@ Acadia Pharmaceuticals Tieszen(858) 261-2950ir@ Sign in to access your portfolio
